Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Jacques Näsström Chief Executive Officer ADDRESS PledPharma AB Grev Turegatan 11 C 114 46 Stockholm TELEPHONE +46 8 679 72 10 FAX +46 8 663 57 25 EMAIL jacques.nasstrom@pledpharma.se YEAR FOUNDED 2006 PledPharma AB www.pledpharma.se FINANCIAL SUMMARY Cash and cash equivalents on June 30 was SEK 68 608k COMPANY PROFILE PledPharma is a Swedish specialty pharma company that develops a new medicine, PledOx®, for prevention of the severe side effects that patients develop as a consequence of chemotherapy treatment of cancer. Many times the treatment cannot be carried out as planned due to very difficult side effects. The current market for supportive cancer care is some SEK 72 billion. PledOx is a medicine within the patent protected substance class PLED, which protects the body’s normal cells against oxidative stress. Oxidative stress is a condition where an overabundance of harmful oxygen molecules (free oxygen radicals) has been formed. We are also evaluating opportunities with PLED substances for other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For more information, please visit www.pledpharma.se MANAGEMENT Jacques Näsström, CEO Marie Bengtson, Clinical Project Director Sven Jacobsson, CMC Johan Stuart, CFO Professor Per Jynge, Medical Advisor Cardiology Erik Kinnman, VP IR and Med. Advisor Neurology Malin Lundgren, Proj. Manager and Dir Regulatory t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Michael Altorfer, Ph.D. Head Corporate Development ADDRESS Hegenheimermattweg 125 CH-4123 Allschwil Switzerland TELEPHONE +41 61 567 16 00 FAX +41 61 567 16 01 EMAIL info@polyphor.com michael.altorfer@polyphor.com YEAR FOUNDED 1996 Polyphor Ltd www.polyphor.com FINANCIAL SUMMARY Polyphor secured cash inflows through operational revenues and capital increases, each of which contributed roughly 50% to the total amount of close to 200 Mio. CHF. COMPANY PROFILE Corporate overview Polyphor is a Swiss research-driven pharmaceutical company developing innovative products with high therapeutic benefit to the patient and providing high quality support to its industry partners engaged in drug discovery. Polyphor has established two complementary innovative, proprietary technology platforms with the aim to discover and develop new medicines for unmet medical needs. Polyphor’s MacroFinder® and PEMfinder® platforms were specifically developed for discovering potent and selective modulators of Protein-Protein Interactions and other challenging targets. Products: Broadly diversified clinical and pre-clinical development portfolio • POL6326 (CXCR4 antagonist) • POL7080 (Pseudomonas-selective antibiotic, novel mode of action) • POL6014 (elastase inhibitor) • GPCR platform (e.g. CXCR7, CCR10) • Protease platform Platforms: Two proprietary technology platforms • PEMfinder® • MacroFinder® Partnering: R&D collaborations with Pharma partners • Boehringer Ingelheim • Novartis Clinical Development Pipeline: Polyphor’s competitive edge is based on its technology platforms which sustain a diversified portfolio of clinical candidates in various therapeutic areas. POL6326 (Phase II) – a CXCR4 antagonist that mobilizes stem cells from the bone marrow to the circulating blood. This effect can be exploited in several ways: • Stem cell transplantation (autologous and allogeneic). • Tissue repair. • Chemosensitization (CXCR4 antagonist to enhance impact of established anti-cancer therapies). POL7080 (Phase II ready) – highly potent Pseudomonas-selective antibiotic with novel mode of action. Successfully completed Phase I clinical trial. POL7080 has been shown to be highly efficacious against a broad panel of clinical isolates, including MDR Pseudomonas strains: • Phase II clinical trial planned to start in Q1, 2013. MANAGEMENT Jean-Pierre Obrecht Ph.D., Co-founder & CEO Daniel Obrecht Ph.D., Co-founder & CSO Christoph Rentsch, CFO Michael Altorfer Ph.D., Head Corporate Development Klaus Dembowsky M.D., Ph.D., Chief Medical Officer Marc Thommen Ph.D., Head Technology Platform Peter Zbinden Ph.D., Head Internal Services Helmut Kessmann Ph.D., Head Business Development t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20:
Speakers Paul Higham, Managing Dire
Page 21 and 22:
Speakers Richard Goodfellow, CEO, S
Page 23 and 24:
Speakers Søren Moller, Managing In
Page 25 and 26:
CONTACT Robert F Burns, PhD Chief E
Page 27 and 28:
CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30:
CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81: CONTACT Dr Erik Buntinx Chief Execu
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?